• SENSEX
    NIFTY 50

Cipla shares rally 4% after it settles litigation with Celgene Corp for cancer drug Revlimid

Updated : December 14, 2020 11:44 AM IST

Celgene has agreed to provide Cipla with a license to Celgene’s patents required to manufacture and sell certain volume-limited amounts of generic lenalidomide in the US.
The specific volume-limited license date and percentages agreed upon with Cipla are confidential.
Cipla shares rally 4% after it settles litigation with Celgene Corp for cancer drug Revlimid

You May Also Like

Live TV

recommended for you

Advertisement